SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-492635"
 

Sökning: id:"swepub:oai:DiVA.org:uu-492635" > Heparin Conjugate P...

Heparin Conjugate Pretreatment of Kidneys From Deceased Donors Before Transplantation : Results From the First-in-human Randomized Phase I Trial

Sedigh, Amir (författare)
Uppsala universitet,Transplantationskirurgi
Lundgren, Torbjörn (författare)
Lindnér, Per, 1956 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för kirurgi,Institute of Clinical Sciences, Department of Surgery
visa fler...
Nordström, Johan (författare)
Magnusson, Peetra (författare)
Uppsala universitet,Klinisk immunologi
Jönsson, Janniz (författare)
Uppsala universitet,Transplantationskirurgi,Klinisk immunologi
Carlsson, Fredrik (författare)
Uppsala universitet,Klinisk immunologi,Corline Biomedical AB, Uppsala, Sweden.
Ploeg, Rutger (författare)
Nuffield Department of Surgical Sciences, Oxford Transplant Centre, University of Oxford, Oxford, United Kingdom.
Lorant, Tomas, 1975- (författare)
Uppsala universitet,Transplantationskirurgi
visa färre...
 (creator_code:org_t)
2022-12-22
2023
Engelska.
Ingår i: Transplantation direct. - : Wolters Kluwer. - 2373-8731. ; 9:1
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background. Pretreating porcine kidneys with corline heparin conjugate (CHC) during hypothermic machine perfusion (HMP) has been shown to reduce preservation injury and improve early kidney function. In this first-in-human phase I study, the safety and tolerability of transplanting CHC-pretreated kidneys was evaluated.Methods. CHC or placebo was added to the preservation solution during HMP of donated kidneys from deceased donors for at least 3 h before transplantation into adult patients. The primary safety endpoint was the number and severity of adverse events (AEs) and serious AEs (SAEs) during the first 30 d after transplantation.Results. In the first 30 d, 66 AEs were reported in 8 patients who received CHC-pretreated kidneys with 39 AEs in 8 patients who received placebo-pretreated kidneys (P = 0.1 in post hoc analysis). The most common AEs were hypertension (CHC, n = 5; placebo, n = 2) and anemia (CHC, n = 5; placebo, n = 2). Most AEs were assessed as mild (58%) or moderate (39%) and not related to treatment (95%). There were 2 SAEs reported in each group. One SAE, considered possibly related to CHC treatment, was a case of severe postprocedural hemorrhage that required reoperation. No patients needed dialysis. There were no observed rejections and no patient deaths.Conclusions. Pretreatment of kidneys with CHC before transplantation was considered safe and tolerable. Efficacy studies are now planned to investigate if CHC can reduce early ischemia-reperfusion injury in humans.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kirurgi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Surgery (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Urology and Nephrology (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy